Alignment of Two Human DLL3 Isoforms (NP_058637 = var 1; NP_928353 = var 2)

```
                1                                                                   80
NP_058637     (1) MVSPRMSGLLSQTVILALIFLPQTRPAGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESPCALG
NP_982353     (1) MVSPRMSGLLSQTVILALIFLPQTRPAGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESPCALG

                81                                                                 160
NP_058637    (81) AALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIETWREELGDQIGGPAWSLLARVAGRRRLAAGGPWAR
NP_982353    (81) AALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIETWREELGDQIGGPAWSLLARVAGRRRLAAGGPWAR

               161                                                                 240
NP_058637   (161) DIQRAGAWELRFSYRARCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSPEHGFCEQPGECRCL
NP_982353   (161) DIQRAGAWELRFSYRARCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSPEHGFCEQPGECRCL

               241                                                                 320
NP_058637   (241) EGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPGPCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGP
NP_982353   (241) EGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPGPCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGP

               321                                                                 400
NP_058637   (321) CFNGGLCVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALRCRCRAGFAGPRCEHDLDDCAGRAC
NP_982353   (321) CFNGGLCVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALRCRCRAGFAGPRCEHDLDDCAGRAC

               401                                                                 480
NP_058637   (401) ANGGTCVEGGGAHRCSCALGFGGRDCRERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASALPAAP
NP_982353   (401) ANGGTCVEGGGAHRCSCALGFGGRDCRERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASALPAAP

               481                                                                 560
NP_058637   (481) PGLRPGDPQRYLLPPALGLLVAAGVAGAALLLVHVRRRGHSQDAGSRLLAGTPEPSVHALPDALNNLRTQEGSGDGPSSS
NP_982353   (481) PGLRPGDPQRYLLPPALGLLVAAGVAGAALLLVHVRRRGHSQDAGSRLLAGTPEPSVHALPDALNNLRTQEGSGDGPSSS

               561                                                  618
NP_058637   (561) VDWNRPEDVDPQGIYVISAPSIYAREVATPLFPPLHTGRAGQRQHLLFPYPSSILSVK          SEQ ID NO. 1
NP_982353   (561) VDWNRPEDVDPQGIYVISAPSIYAREA------------------------------          SEQ ID NO. 2
```

FIG. 1



Schematic Representation of DLL3 Protein
ECD
N-terminal domain
DSL
6 EGF-like Domains
Tumor Cell

FIG. 2

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Light Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.3	QIVLTQSPAIMSVSLGERVTMTC	TASSSVSSSYLH	WYQQKPGSSPKLWIY	STSNLAS	GVPARFSGSGSGTSYFFTISSMEAEDAATYYC	HQYHRSPFT	FGAGTKLKIR	21
SC16.4	DIQMTQTTSSLSASLGDRVTISC	RASQDISNYLN	WYQQKPDGTVKLLIY	YTSRLHS	GVPSRFSGSGSGTDYSLTISNLELEDIATYFC	QQGDMLPWT	FGGGTKLEIK	25
SC16.5	QIVLTQSPAIMSASPGEKVTMTC	SASSSVSYMH	WYQQKSGTSPKRWIY	DTSKLAS	GVPARFSGSGSGTSYSLTISSMEAEDAATYYC	QQWTRNPLT	FGAGTKLELK	29
SC16.7	NIMMTQSPSSLAVSAGEKVTMSC	KSSQSVLYSSNQKNYLA	WYQQKPGQSPKLLIY	WASTRES	GVPDRFTGSGSGTDFTLTISTVQVEDLAVYYC	HQYLSSWT	FGGGTKLEIK	33
SC16.8	EIQMTQSPSSMSASLGDRITITC	QATQDIVKNLN	WYQQKPGKPPSFLIY	YAIELAE	GVPSRFSGSGSGSDYSLTISNLESEDFADYYC	LQFYEFPFT	FGAGTKLELK	37
SC16.10	QIVLTQSPAIMSASLGERVTMTC	TASSSVSSSYLH	WYQQKPGSSPKLWIY	STSNLAS	GVPTRFSGSGSGTSYSLTISSMEAEDAATYYC	HQYHRSPFT	FGSGTKLEIK	41
SC16.11	DVEMTQTPLTLSVTIGQPASISC	KSSQSLSDSDGKTYLN	WMFQRPGRSPKRLIY	LVSKLDS	GVPDRFTGSGSGTDFTLKISRVEAEDLGVYYC	WQGKHFPWT	FGGGTKLEIK	45
SC16.13	QIVLTQSPALVSASPGEKVTMTC	SASSSVSYMY	WYQQKPRSSPKPWIY	LTSNLAS	GVPARFSGSGSGTSYSLTISSMEAEDAATYYC	QQWRSNPFT	FGSGTKLEIK	49
SC16.15	DIQMTQSPASLAASVGETVAITC	RASENIYYNLA	WYQQKQGKSPQLLIY	TANSLED	GVPSRFSGSGSGTQYSLKINSMQPEDSATYFC	KQAYDVPPT	FGGGTKLEIK	53
SC16.18	DIQMTQTTSSLSASLGDRVTISC	RASQNIINYLN	WYQQKPDGTVKLLIY	YTSRLHS	GVPSRFSGSGSGTDYSLTISNLEPEDIATYYC	QQYSERPYT	FGGGTKLEIK	57
SC16.19	DIQMTQSPSSLSASLGGKVTFTC	KASQDIHKYVA	WYQHKPGKGPRLLIH	YTSTLQP	GISSRFSGSGSGRDYSFSISNLEPEDIATYYC	LQYNNLYT	FGGGTKLEIK	61
SC16.20	EIQMTQSPSSMSASLGDRITITC	QATQDIVKNLN	WYQQKPGKPPSFLIY	YATELAE	GVPSRFSGSGSGSDYSLTIRNLESEDFADHYC	LQFYEFPFT	FGAGTKLELK	65
SC16.21	DIVMTQSPSSLAMSVGQKVTMSC	KSSQSLLNSSNQKNYLA	WYQQEPGQSPKLLVS	FASTRES	GVPDRFTGSGSGTDFTLTISGVQAEDLAVYYC	QQHYSIPLT	FGAGTKLELK	69
SC16.22	DIQMTQTTSSLSASLGDRVTISC	RASQDIKNYLN	WYQQKPDGTVKPLIY	YTSRVHS	GVPSRFSGSGSGTDYSLTISNLEQEDIATYFC	QQGYTLPFT	FGSGTKLE<u>IK</u>	73
SC16.23	QIVLTQSPAIMSASPGEKVTLTC	SASSSVSSRYLY	WYQQKPGSSPKLWIY	STSNLAS	GVPARFSGSGSGTSYSLIISSMEAEDAASYFC	HQWSNYPLT	FGAGTKLELK	77
SC16.25	QIVLTQSPAIMSASPGEKVTMTC	SASSSVSYMH	WYQQKSGTSPKRWIY	DSSKLAS	GVPARFSGSGSGTSYSLTISSMEAEDAATYYC	QQWSSNPLT	FGAGTKLELK	81
SC16.26	DVEMTQTPLTLSVTIGQPASISC	KSSQSLSDSDGKTYLN	WMFQRPGRSPKRLIY	LVSKLDS	GVPDRFTGSGSGTDFTLKISRVEAEDLGVYYC	WQGKHFPWT	FGGGTKLEIK	85
SC16.29	QIVLTQSPAIMSASPGEKVTITC	SASSSVSYMH	WFQQKPGTSPKLWIY	TTSNLAS	GVPARFSGSGSGTSYSLTVSRMEAEDAATYYC	QQRSLYPYT	FGGGTKVEIK	89
SC16.30	QIVLTQSPTIMSASLGERVTMTC	TASSSVTSSYLH	WYQQKPGSSPKLWIY	STSNLAS	GVPARFSGSGSGTSYSLTISSMEAEDAATYYC	HQFHRSPFT	FGSGTKLEIK	93
SC16.31	DIVLTQSPLSLPVNIGDQASISC	KSTKSLLNSDGFTYLD	WYLQRPGQSPQFLIY	LVSNRFS	GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYC	FQSNYLPLT	FGAGTKLELR	97

FIG. 3A

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Light Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.34	SIVMTQTPKFLLVSAGDRVTITC	KASQSVSNDVA	WYQQKPGQSPKLLIY	YASNRYS	GVPDRFTGSGYGTDFTFTISTVQAEDLAVYFC	QQDYSSPWT	FGGGTKLEIK	101
SC16.35	DIQMTQTTSSLSASLGDRVTISC	RASQDISNYLN	WYQQKPDGTVKLLIY	YTSRLHS	GVPSRFSGSGSGTDYSLTISNLEQEDIATYFC	QQGNTLPYT	FGGGTKLEIK	105
SC16.36	ETTVTQSPASLSVTTGEKVTIRC	ITTPDIDDDMN	WYQQKPGEPPNLLIS	EGNSLRP	GVPSRFSSSGYGTNFVFTIENTLSEDVADYYC	LQSDNMPFT	FGSGTKLEIK	109
SC16.38	QIVLTQSPAIMSASPGEKVTMTC	SASSSINYMH	WYQQKPGTSPKRWIY	DTSKLAS	GVPARFSGSGSGTSYSLTISSMEAEDAATYYC	HQRSTWT	FGGGTKLEIK	113
SC16.41	DIQMTQTTSSLSASLGDRVTISC	RASQDVINYLN	WYQQKPDGTVKLLIY	YTSRLHS	GVPSRFSGSGSRTDYSLTISNLEPEDIATYYC	QQYSERPYT	FGGGTKLEIK	117
SC16.42	DVLMTQSPLSLSVSLGDQASISC	RSSQNIVHSDRYTYLE	WYLQKPGQSPKLLIY	GVSNRFS	GVPDRFSGSGSGTDFTLKISRVEAEDMGVYYC	FQGTHVPYT	FGGGTKLEIK	121
SC16.45	EIQMTQSPSSMSASLGDRITITC	QATQDIVKNLN	WYQQKPGKPPSFLIY	YATELAE	GVPARFSGSGSGSDYSLTISNLESEDFADYHC	LQFYEFPFT	FGAGTKLELK	125
SC16.47	DVVLTQSPLSLPVNIGDQASISC	KSTKSLLNSDGFTYLD	WYLQRPGQSPQFLIY	LVSNRFS	GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYC	FQSNYLPLT	FGAGTKLELR	129
SC16.49	DIKMTQSPSSMYASLGERVTITC	KASQDINSYLS	WFQQKPGKSPKTLIY	RANRLVD	GVPSRFSGSGSGQDYSLTITSLEYEDMGIYYC	LQYDEFPLT	FGAGTKLELK	133
SC16.50	DIQMTQTTSSLSASLGDRVTISC	RASQDISNYLN	WYQQKPDGTVKLLIY	YTSRLHS	GVPSRFSGSGSGTDYSLTISNLEQEDIATYFC	QQGNTLRT	FGGGTKLEIK	137
SC16.52	DIQMIQSPSSMFASLGDRVSLSC	RASQGIRGTLD	WYQQKPNGTIKLLIY	STSNLNS	GVPSRFSGSGSGSDYSLTISSLESEDFADYYC	LQRNAYPLT	FGAGTKLELK	141
SC16.55	DIKMTQSPSSMYASLGERVTITC	KASQDINSYLN	WFQQKPGKSPKTLIY	RANRLVD	GVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC	LQYDEFPYT	FGGGTKLEIK	145
SC16.56	SIVMTQTPKFLLVSAGDRVTITC	KASQSVSNDVV	WYQQKPGQSPKLLIY	YASNRYT	GVPDRFAGSGYGTDFSFTISTVQAEDLAVYFC	QQDYTSPWT	FGGGTKLEIR	149
SC16.57	DIVMTQSHKFMSISVGDRVSITC	KASQDVSIFVA	WYQQKPGQSPKLLIY	SASYRYT	GVPDRFTGSGSGTDFIFTISSVQAEDLAVYYC	QQHYGTPFT	FGSGTKLKIR	153
SC16.58	DIQMTQSPASLSSSVGETVTITC	RASENIYSYLA	WYQQKQGKSPQLLVY	NAKTLAE	GVPSRFSGSGSGTQFSLKINSLQPEDFGTYYC	QHHYDSPLT	FGAGTKLELR	157
SC16.61	DIVMTQSTSSLAMSVGQKVTMSC	KSSQSLLNSSNQKNYLA	WYQQEPGQSPKLLVS	FASTRES	GVPDRFTGSGSGTDFTLTISGVQAEDLAVYYC	QQHYSIPLT	FGAGTKLELK	161
SC16.62	DIKMTQSPSSMYASLGERVTITC	KASQDINSFLS	WFQRKPGKSPKTLIY	RANRLVD	GVPSRFTGSGSGQEFSLTISSLEYEDLGIYYC	LQYDEFPYT	FGGGTKLEIK	165
SC16.63	QIVLTQSPAIMSASPGEKVTMTC	SASSSVSYMY	WYQQKSGTSPKRWIY	DTSKLAS	GVPARFSGSGSGTSYSLTISSMEAEDAATYYC	QQWSSNPYT	FGGGTKLEIK	169
SC16.65	QIVLTQSPALMSASPGEKVTMTC	SVTSSVSYMY	WYQQKPRSSPKPWIY	LTSNLAS	GVPARFSGSGSGTSYSLTISSVEAEDAATYYC	QQWRNNPFT	FGSGTKVEIK	173
SC16.67	QAVVTQESALTTSPGETVTLTC	RSSTGAVTTSNYAN	WIQEKPDHLFTGLIG	GTNNRAP	GVPARFSGSLIGDKAALTITGAQTEDEAIYFC	GLWYSNHLV	FGGGTKLTVL	177
SC16.68	ETTVTQSPAFLSVATGEKVTIRC	ITSTDIDDDMN	WYQQKPGEPPNVLIS	EGNTLRP	GVPSRFSSSGYGTDFVFTIENTLSEDVADYYC	LQSDNMPLT	FGAGTKLELK	181
SC16.72	ENVLTQSPAIMSASLGEKVTMSC	RASSSVNYMS	WYQQKSDASPKLWIY	YTSNLAP	GVPARFSGSGSGNSYSLTISSMEGEDAATYYC	QQFTSSPYT	FGGGTKLEIK	185

FIG. 3A cont.

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Light Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.73	DIQMTQSPSSLSASLGERVSLTC	RASQDIGYSLN	WLQQEPDGTIKRLIY	ATSSLDS	GVPKRFSGSRSGSDYSLTISSLESEDFVDYYC	LQYASSPWT	FGGGTKLEIK	189
SC16.78	DIKMTQSPSSMYASLGERVTITC	KASQDINSYLS	WFQQKPGRSPKTLIY	RANRLVD	GVPSRFSGSGSGQDYSLTISSLDYEDMGIYYC	LQYDEFPFT	FGSGTKLEIK	193
SC16.79	DIVMSQSPSSLAVSAGEKVTMSC	KSSQSLLNSRTRKNYLA	WYQQKPGQSPKLLIY	WASTRES	GVPDRFTGSGSGTDFTLTISSVQAEDLAVYYC	KQSYNLYT	FGGGTKLKIK	197
SC16.80	ETTVTQSPASLSMAIGEKVTIRC	ITSTDIDDDMI	WYQQKPGEPPKLLIS	EGNTLRP	GVPSRFSSSGYGTDFVFTIENMLSEDVADYYC	LKRDDLPYT	FGGGTQVEIK	201
SC16.81	QIVLTQSPAIMSASLGERVTLTC	TASSSVSSSYLH	WYQQKPGSSPKLWIY	STSNLAS	GVPTRFSGSGSGTSYSLRISSMEAEDAATYYC	HQYNRSPLT	FGAGTKLELK	205
SC16.84	DIQMTQSPSSLSASLGGKVTITC	KASQDIKKYIA	WYQHKPGKGPRLLIH	YTSTLEP	GIPSRFSGSGSGRDYSFSISNLEPEDIATYYC	LQYDILWT	FGGGTKLEIK	209
SC16.88	ENVLTQSPAIMAASLGQKVTMTC	SASSSVSSSYLH	WYQQKSGASPKPLIH	RTSNLAS	GVPARFSGSGSGTSYSLTISSVEAEDDATYYC	RQWSGYPWT	FGGGTKLEIK	213
SC16.101	QIVLTQSPAIMSASLGERVTMTC	TASSSVSSSYLH	WYQQKPGSSPKLWIY	STSNLAS	GVPARFSGSESGTSYSLTISNMEAEDAATYYC	HQYHRSPFT	FGSGTKLEIK	217
SC16.103	DIVLTQSPASLAVSLGQRATISC	RASKSVSTSGYSYMH	WYQQKPGQPPKLLIY	LASNLES	GVPARFSGSGSGTDFTLNIHPVEEEDAATYYC	QHSRELPLT	FGAGTKLELK	221
SC16.104	QIVLSQSPAILSASPGEKVTMTC	RASSSVSYIH	WYRQKPGSSPKPWIY	ATSNLAS	GVPARFSGSGSGTSYSLTISRVEAEDAATYYC	QQWSSNPPT	FGAGTKLELK	225
SC16.105	DIVMTQSHKFMSTSVGDRVSITC	KASQDVGTAVA	WYQQKPGQSPKLLIY	WASIRHT	GVPDRFTGSGSGTDFTLTISNVQSEDLADYFC	QQYSSYPLT	FGAGTKLELK	229
SC16.106	DIKMTQSPSSMYASLGERVTITC	KASQDINSYLS	WFQQKPGKSPKTLIY	RANRLVD	GVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC	LQYDEFPFT	FGSGTKLEIK	233
SC16.107	DIVMTQSHKFMSTSVGDRVSITC	KASQDVNTAVG	WYQQKPGQSPKLLIY	SASYRYT	GVPDRFTGSGSGTDFTFTISSVQAEDLAVYYC	QQHYSSPYT	FGGGTKVEIK	237
SC16.108	DIQMTQSPASLSASVGETVTITC	RASENIYSYLA	WYQQKQGKSPQLLVY	NAKTLAE	GVPSRFSGSRSGSQFSLKINSLQPEDFGSYYC	QHHYGTPYT	FGGGTKLEIK	241
SC16.109	QIVLTQSPAIMSASPGEKVTMTC	SASSSVSYMY	WYQQKPGSSPRLLIY	DTSNLAS	GVPVRFSGSGSGTSFSLTISRMEAEDTATYYC	QEWSGNPLT	FGDGTKLELK	245
SC16.110	NIVMTQTPKFLLVSAGDRVTITC	KASQSVSNDVA	WYQQKPGQSPKLLIY	YASNRYT	GVPDRFTGSGYGTDFTFTISTVQAEDLAVYFC	QQDYSSPPT	FGGGTKLEIK	249
SC16.111	DIQMTQSPASLAASVGETVTITC	RASENIYYSLA	WYQQKQGKSPQLLIY	NANSLED	GVPSRFSGSGSGTQYSMKINSMQPEDTATYFC	KQTYDVPLT	FGAGTKLELK	253
SC16.113	DVVMTQTPLTLSVTIGQPASISC	KSSQSLLDSDGTTYLN	WLLQRPGQSPKRLIY	LVSKLDS	GVPDRFTGSGSGTDFTLKISRVEAEDLGVYYC	WQGTHFPLT	FGAGTKLELK	257
SC16.114	QIVLSQSPAILSASPGEKVTMTC	RASSSVSYMH	WYQQKPGSSPKPWIY	ATSNLAS	GVPARFSGSGSGTSYSLTISRVEAEDAATYYC	QQWSSNPYT	FGGGTKLEIK	261
SC16.115	DVVMTQTPLTLSVTIGQPASISC	KSSQSLLDSDGTTYLN	WLLQRPGQSPKRLIY	LVSKLDS	GVPDRFTGSGSGTDFTLKISRVEAEDLGVYYC	WQGTHFPLT	FGAGTKLELK	265

FIG. 3A cont.

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Light Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.116	DIVMTQSPSSLTVTAGEKVTMSC	TSSQSLLTSGNQKNYLT	WYQQKPGQPPKLLIY	WASTRES	GVPDRFTGSGSGTDFTLTISSLQAEDLAVYYC	QNDYSLT	FGAGTKLELK	269
SC16.117	DIQMNQSPSSLSASLGDTITITC	HVSQNINVWLS	WYQQKPGNIPKLLIQ	KASNLHT	GVPSRFSGSGSGTGFTLTISSLQPEDIATYYC	QQGQSYPFT	FGSGTKLEIK	273
SC16.118	DIVLTQSPASLAVSLGQRATISC	KASQSVDYDGDSYLT	WYQQKPGQPPKLLIY	AASNLES	GIPARFSGSGSGTDFTLNIHPVEEEDAATYYC	QQSNEDPYT	FGGGTKLEIK	277
SC16.120	DIVMSQSPSSLAVSVGEKVTMSC	KSSQSLLYSSTQKNYLA	WYQQKPGQSPKLLIY	WASTRES	GVPDRFTGSGSGTDFTLTISSVKAEDLAVYYC	QQYYSYPYT	FGGGTKLEIK	281
SC16.121	QIVLTQSPAIMSASPGEKVTITC	SASSSVSYMH	WFQQKPGTSPKLWIY	STSNLAS	GVPARFSGSGSGTSYSLTISRMEAEDAATYYC	QQRSSYPPT	FGGGTKLEIK	285
SC16.122	DIVMTQSQKFMSTSVGDRVSVTC	KASQNVGTNVA	WYQQKPGQSPKVLIY	SASYRYS	GVPDRFTGSGSGTDFTLTISNVQSEDLAEFFC	QQYNSYPLT	FGGGTKLEIK	289
SC16.123	QIVLTQSPAIMSASLGERVTMTC	TASSSVSSSYLH	WYQQKPGSSPKLWIY	STSNLAS	GVPARFSGSGSGTSYSLTISSMETEDAATYYC	HQYHRSPFT	FGSGTKLEIK	293
SC16.124	DIQMTQSPASQSASLGESVTITC	LASQTIGTWLA	WYQQKPGKSPQLLIS	AATSLAD	GVPSRFSGSGSGTKFSFKISSLQAEDFVSYYC	QQLYSTPWT	FGGGTKLEIK	297
SC16.125	DIQMNQSPSSLSASLGDTITITC	HASQNINVWLS	WYQQKPGNIPKLLIY	KASILHT	GVPSRFSGSGSGTGFTLTISSLQPEDIATYSC	QQGQSYPYT	FGGGTKLEIK	301
SC16.126	DIQMNQSPSSLSASLGDTITITC	HASQNINVWLS	WYQQKPGNIPKLLIY	KASNLHT	GVPSRFSGSGSGTGFTLTISSLQPEDIATYYC	QQGQSYPFT	FGSGTKLEIK	305
SC16.129	DIQMTQSPASQSASLGESVTITC	LASQTIGTWLA	WYQQKPGKSPQLLIY	AATSLAD	GVPSRFSGSGSGTKFSFKISSLQAEDFVSYYC	QQLYSTPYT	FGGGTKLEIK	309
SC16.130	DIQLTQSPASLSASVGETVTITC	RASGSIHNYLA	WYQQKQGKSPQLLVY	NAKTLVD	GVPSRFSGSGSGTQYSLKINSLQPEDFGYYYC	QHFWTTPWT	FGGGTKLEIK	313
SC16.131	DIQMNQSPSSLSASLGDTITITC	HVSQNINVWLS	WYQQKPGNIPKLLIQ	KASNLHT	GVPSRFSGSGSGTGFTLTISSLQPEDIATYYC	QQGQSYPFT	FGSGTKLEIK	317
SC16.132	DIQMTQSPASQSASLGESVTITC	LASQTIGTWLA	WYQQKPGKSPQLLIY	AATSLAD	GVPSRFSGSGSGTKFSFKISSLQAEDFVSYYC	QQLYSTPWT	FGGGTKLEIK	321
SC16.133	SIVMTQTPKFLLVSAGDRVTITC	KASQSVSNDVA	WYQQKPGQSPKLLIY	CASNRYT	GVPDRFTGSGYGTDFTFTISTVQAEDLAVYFC	QQDYSSPLT	FGAGTKLELK	325
SC16.134	DIVLTQSPASLAVSLGQRATISC	KASQSVDHAGDSYMN	WYQQKPGQPPKLLIY	AASNLES	GIPARFSGSGSGTDFTLNIHPVEEEDAATYYC	QQSNEDPYT	FGGGTKLEIK	329
SC16.135	DIKMTQSPSSMYASLGERVTITC	KASQDINRYLS	WFQQKPGKSPKTLIY	RANRLVD	GVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC	LQYDEFPFT	FGSGTKLEIK	333
SC16.136	DIQMTQSPASLSASVGETVTITC	RASGNIHNYLA	WYQQKQGKSPHLLVY	NAKTLAD	GVPSRFSGSGSGTQYSLKINSLQPEDFGSYYC	QHFWSTPWT	FGGGTKLEIK	337
SC16.137	QIVLTQSPAIMSASLGEEITLTC	SASSSVSYMH	WYQQKSGTSPKLLIY	STSNLAS	GVPSRFSGSGSGTFYSLTISSVEAEDAADYYC	HQWSSYHT	FGGGTKLEIK	341

FIG. 3A cont.

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Light Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.138	DIQMTQSPASQSASLGESVTITC	LASQTIGTWLA	WYQQKPGKSPQLLIY	SATSLAD	GVPSRFSGSGSGTKFSFKISSLQAEDFVSYYC	QQLYSTPWT	FGGGTKLEIK	345
SC16.139	DIVMTQSHKFMSTSVGDRVSITC	KASQDVNTAVG	WYQQKPGQSPKLLIY	SASYRYT	GVPDRFTGSGSGTDFTFTISSVQAEDLAVYYC	QQHYSSPYT	FGGGTKLEIK	349
SC16.140	DIVLTQSLASLAVSLGQRATISC	RASKSVSTSGYSYMH	WYQQKPGQPPKLLIY	LASNLES	GVPARFSGSGSGTDFTLNIHPVEDEDAATYYC	QHSRELPFT	FGGGTKLEIK	353
SC16.141	DIKMTQSPSSMYASLGERVTITC	KASQDINSYLS	WFQQKPGKSPKTLIY	RANRLVD	GVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC	LQYDEFPFT	FGSGTKLEIK	357
SC16.142	DIKMTQSPSSMYASLGERVTITC	KASQDINNYLS	WFQQKPGKSPKTLIY	RANRLVD	GVPSRFSGSGSGQDYSLTISSLEYEDMGIYYC	LQYDEFPYT	FGGGTKLEIK	361
SC16.143	DVLMTQTPLSLPVSLGDQASISC	RSSQSIVHSNGNTYLE	WYLQKPGQSPKLLIY	KVSNRFS	GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYC	FQGSHVPLT	FGAGTKLELK	365
SC16.144	SIVMTQTPKFLLVSAGDRVTITC	KASQSVSNDVG	WYQQKPGQSPKLLIY	YASNRYN	GVPDRFTGSGYGTDFTFTISTVQAEDLAVYFC	QQDYSSPWT	FGGGTKLEIK	369
SC16.147	DIQMTQTASSLSASLGDRVTISC	RASQDINNYLN	WYQQKPDGTVKLLIY	YTSRLHS	GVPSRFSGSGSGTDYSLTISILEQEDIATYFC	QQGDTLPWT	FGGGTKLEIK	373
SC16.148	QIVLTQSPAIMSASPGEKVTMTC	SASSSVSYMY	WYQQKPGSSPRLLIY	DTSNLAS	GVPVRFSGSGSGTSYSLTISRMEAEDTATYYC	QEWSNNPLT	FGDGTKLELK	377
SC16.149	DIQMNQSPSSLSASLGDTITITC	HASQNINVWLS	WYQQKPGNIPKLLIY	KASHLHT	GVPSRLSGSGSGTGFTLTISSLQPEDIATYYC	QQGQSYPFT	FGSGTTLEIK	381
SC16.150	DIVMSQSPSSLTVSVGEKVTMSC	MSSQSLLYSSTQKNYLA	WYQQKPGQSPKLLIY	WASTRES	GVPDRFTGSGSGTDFTLTISSVKAEDLAVYYC	QQYYSYPYT	FGGGTKLEIK	385

FIG. 3A cont.

Amino Acid Sequences of Exemplary Humanized anti-DLL3 Antibody Light Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
hSC16.13	DIQMTQSPSSLSASVGDRVTITC	SASSSVSYMY	WYQQKPGKAPKLLIY	LTSNLAS	GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC	QQWRSNPFT	FGQGTKLEIK	389
hSC16.15	AIQLTQSPSSLSASVGDRVTITC	RASENIYYNLA	WYQQKPGKAPKLLIY	TANSLED	GVPSRFSGSGSGTDFTLTISSLQPEDFATYFC	KQAYDVPPT	FGGGTKLEIK	393
hSC16.25	EIVLTQSPDFQSVTPKEKVTITC	SASSSVSYMH	WYQQKPDQSPKLLIK	DSSKLAS	GVPSRFSGSGSGTDFTLTINSLEAEDAATYYC	QQWSSNPLT	FGQGTKLEIK	397
hSC16.34	DIQMTQSPSSLSASVGDRVTITC	KASQSVSNDVA	WYQQKPGKVPKLLIY	YASNRYS	GVPSRFSGSGSGTDFTLTISSLQPEDVATYFC	QQDYSSPWT	FGGGTKVEIK	401
hSC16.56	EIVMTQSPATLSVSPGERATLSC	KASQSVSNDVV	WYQQKPGQAPRLLIY	YASNRYT	GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC	QQDYTSPWT	FGQGTKLEIK	405

FIG. 3A cont.

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Heavy Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.3	QVTLKESGPGILQPSQTLSLTCSFSGFSLS	TSGMGVG	WIRQPSGKGLEWLA	HIWWDDVKRYNPALKS	RLTISKDTSSSQVFLKIASVDTADTATYYCAR	IADYGGDYYAMDY	WGQGTSVTVSS	23
SC16.4	QIQLVQSGPELKKPGETVKISCKASGYTFT	DYSMH	WVKQAPGKGLKWMG	WINTETGEPGYADDFKG	RFAFSLETSASTAYLQINNLKNEDTATYFCAR	YDGYAMDY	WGQGTSVTVSS	27
SC16.5	QVTLKESGPGILQPSQTLSLTCSFSGFSLS	TSGMGVG	WIRQPSGEGLEWLA	DIWWDDNKYYNPSLKS	RLTISKDTSSNQVFLKITSVDTADTATYYCAR	RVNYVYDPYYAMDY	WGQGTSVTVSS	31
SC16.7	EVQLQQSGPELVKPGASVKISCKASGYSFT	GYKMH	WVKQSHVKSLEWIG	RINPYNGATSYNQNFKD	KATLTVDKSSSTAYMDLHSLTSEDSAVYFCAR	GDYRYDWFAY	WGQGTLVTVSA	35
SC16.8	QAQLQQSGAELVRPGTSVKVSCKASGYAFT	NYLIE	WVKQRPGQGLEWIG	VINPGTGGTNYNENFKG	KATLTADKSSSTAYMQLSSLTSDDSAVYFCAR	SPYDYHEGAMDY	WGQGTSVTVSS	39
SC16.10	QVTLKESGPGILQSSQTLSLTCSFSGFSLS	TSGMGVG	WIRQPSGKGLEWLA	HIWWDDVKRYNPVLKS	RLTISKDTSSSQVFLKIASVDTADTATYYCAR	LVDDLYYFDY	WGQGTTLTVSS	43
SC16.11	QIQLVQSGPELKKPGETVKISCKASGYTFT	DYSMH	WVKQAPGKGLKWMG	WINTETVEPTYADDFMG	RFAFSLETSASTAFLQINNLENEDTATYFCAR	FGSYAMDY	WGQGTSVTVSS	47
SC16.13	QVTLKESGPGILQPSQTLSLTCSFSGFSLS	TSGMGVG	WIRQPSGKGLEWLA	HIWWDDVKRYNPALKS	RLTISKDTSSSQVFLKIASVDTADTATYYCAR	IVSFDNDVVSAMDY	WGQGTSVTVS**S**	51
SC16.15	QVQLQQSGAELAKPGASVKMSCKASGYTFT	RYWIH	WIKQRPGQGLEWIG	YINPTTVYTEFNQNFKD	KATLTADKSSTTASMQLSSLTSEDSAVYYCAR	GGSNFFDY	WGQGTTLTVSS	55
SC16.18	EVKLEESGGGLVQPGESMKLSCAASGFTFS	DAWMD	WVRQSPEKGLEWVA	EIRNKANNHATYYAESVKG	KFTISRDDSKSRVYLQMNNLRAADTGIYYCTA	YSNFAY	WGQGTLVTVST	59
SC16.19	EVQLQQSGAELVRPGASVKLSCTASGFNIK	DSLLH	WVKQRPEKGLEWIG	WIDPEDGETKYAPNFQD	KATITTDSSSNTAYLQLISLTSVDTAIYYCAY	GNYVRHFDY	WGQGTTLTVSS	63
SC16.20	QVQLQQSGTELVRPGTSVRVSCKASGYAFG	NHLIE	WVKQRPGQGLEWIG	VINPGTGGTHYNEKFKD	KARLTADKSSNTAYMHLNSLTSDDSAVYFCAR	SPYDYHEGAMDY	WGQGTSVTVSS	67
SC16.21	QVQLQQSGPELVKPGASVKISCKASGYAFS	SSWMN	WVKQRPGKGLEWIG	RIYPGDGDTNYNGKFKG	KATLTADKSSSTAYMQLSSLTSEDSAVYFCAM	GIYNYDGSRYYSMDY	WGQGTSVTVSS	71
SC16.22	QVQLQQPGAELVKPGASVKLSCKASGYTFT	TYWMH	WVKQRPGQGLEWIG	EIDPSDSYTYYNQKFKG	KATLTVDKSSSTAYMQLSSLTSEDSAVYYCAR	GDYGNPYAMDY	WGQGSSVTVSS	75
SC16.23	QVTLKESGPGILQPSQTLSLTCSFSGFSLS	TSNTGIG	WIRQPSGTGLEWLA	HIWWNDDKYYNPSLKS	RLTISKETSNNQVFLKITNVDTADTASYFCVQ	IGRDYSNYAWYFDV	WGAGTTVTVSS	79
SC16.25	QVTLKESGPGILQPSQTLSLTCSFSGFSLS	TSGMGVG	WIRQPSGEGLEWLT	DIWWDDNKYYNPSLKS	RLTISKDTSSNQVFLNITSVDTADTATYYCAR	RVNYYYDPYYAMDY	WGQGTSVTVSS	83
SC16.26	QIQLVQSGPELKKPGETVKISCKASGYSFT	DYSMH	WVKQAPGKGLKWMG	WINTETVEPTYADDFMG	RFAFSLETSASTAFLQINNLENEDTATYFCAR	FGSYAMDY	WGQGTS**VTVSS**	87
SC16.29	QVQLQQSGAELARPGASVKLSCKASGYTFT	DQYIN	WVKQRTGQGLEWIG	EIYPGRGNTYYNEKFKG	KATLTADKSSSTAYMQLSSLTSEDSAVYFCAR	EDGGYDDAWFAY	WGQGTLVTVSA	91
SC16.30	QVTLKESGPGILQPSQTLSLTCSFSGFSLS	TSGMGVG	WIRQPSGKGLEWLA	HIWWDDVKRYKPALKS	RLTVSKDTSSNQVFLKIATVDAADTGTYYCAR	IVDGHPPFAY	WGQGTLVTVSA	95
SC16.31	EVQLQQSGPELVKPGASVKISCKASGYSFS	RFYMH	WVKQSPENSLEWIG	EINPSTGGTSYNQKFKG	KATLTVDKSSSTAYMQLKSLTSEESAVYYCTR	GYGSNWYFDV	WGAGTTVTVST	99

FIG. 3B

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Heavy Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.34	QIQLVQSGPELKRPGETVKISCKASGYTFT	NYGMN	WVKQAPGKGLKWMG	WINTYTGDPTYADDFKG	RFAFSLETSASTAYLQINNLKNEDTATYFCAR	IGGNSPSDY	WGQGTSLTVSS	103
SC16.35	DVQLQESGPGLVKPSQSLSLTCTVTGYSIT	SDYAWN	WIRQFPGNKLEWMG	YISYSGSTSYNPSLKS	RISITRDTSKNQFFLQLNSVTTEDTATYYCAR	FYYGSSYAMDY	WGQGTSVTVSS	107
SC16.36	QVQLQQSGAELAKPGASVKMSCKASGYTFT	TYWMH	WVKQRPGQGLEWIG	YINPSSGYTEYNQKFKD	KATLTADKSSSTAYMQLSSLTSEDSSVYYCAR	KGSNRGFAY	WGQGTLVTVSS	111
SC16.38	EVQLQQSGAELVKPGASVKLSCTVSGFNIK	DTYIH	WVKQRPEQGLEWIG	RIDPANGNTKYDPKFQG	KATITADTSSNTAYLQLSSLTSEDTAVYYCAR	PTGYFEY	WGQGTTLTVSS	115
SC16.41	EVKLEESGGGLVQFGGSMKLSCAASGFTFS	DAWMD	WVRQSPEKGLEWVA	EIRNKANNHATYYPESVKG	RFTISRDDSKSRVYLQMNNLRAEDTGIYYCTG	YSSFAY	WGQGTLVTVSA	119
SC16.42	QIQLVQSGPELKKPGETVKISCKASGYTFT	TAGMQ	WVQKMPGKGFKWIG	WINTHSGEPKYADDFKG	RFAFSLETSASTAYLQISNLKDEDTATFFCAP	LWSDSSFAY	WGQGTLVTVSA	123
SC16.45	QVQLQQSGADLVRPGTSVKVSCKASGYSFT	NYLIE	WVKQRPGQGLEWIG	VINPGSGGTHYNEKFKD	KAVLTADKSSTTAHMQLSSLTSDDSAVYFCAR	SPYDYNDGAMDY	WGQGTSVTVSS	127
SC16.47	EVQLQQSGPELVKPGASVKISCKASGYSFS	RFYMH	WVKQSPENSLEWIG	EINPSTGGTSYNQKFKG	KATLTVDKSSSTAYMQLKSLTSEESAVYYCTR	GYGSNCYFDV	WGAGTTVTVST	131
SC16.49	QVQLQQSGPELVKPGTLVKISCKASGYTFT	SYDIN	WVKQRPGQGLEWIG	WIYPGDGNTKYSEKFKG	KATLTADKSSSTAYMQLTSLTSENSAVYFCAR	DYDYPFAY	WGQGTLVTVSA	135
SC16.50	EVQLVECGGCLVKPGGYLKLSCAASGFTFS	SYAMS	WVRQSPEKRLEWVA	EISIGGSYTYYPDTVTG	RFTISRDNAKNTLYLEMSSLRSEDTAMYYCAR	EGYDYDVRAMDY	WGQGTSVTVSS	139
SC16.52	QVQLKESGPGLVAPSQSLSITCAVSGFSLT	SFAIH	WFRKPPGKGLEWLG	VIWTGGTTNYNSALMS	RLSISKDNSKSQVFLKMNSLQTDDTAMYYCAR	DDYDNNYAMDY	WGQGTSVTVSS	143
SC16.55	EVQLVESGGGLVQPKGSLKLSCAVSAFTFT	TYAMN	WVRQAPGKGLEWVA	RIRNKSNNYATYYADSVKD	RFTISRDDSQSMLYLQMNNLKIEDTAMYYCVF	YYDYVY	WGQGTLVTVSA	147
SC16.56	QIQLVQSGPELKKPGETVKISCKASGYTFT	NYGMN	WVKQAPGKGLKWMA	WINTYTGEPTYADDFKG	RFAFSLETSASTASLQIINLKNEDTATYFCAR	IGDSSPSDY	WGQGTTLTVSS	151
SC16.57	EVKLVESGGDLVKPGGSLKLSCAASGFAFS	SYDMS	WVRQTPEKRLEWVA	TISSGGSYTYYPDSVKG	RFTISRDNVRDTLYLQMSSLRSEDTALYYCAR	QAIGTYFDY	WGQGTTLTVSS	155
SC16.58	DVQLVESGGGLVQPGGSRKLSCAASGFTFS	SFGMH	WVRQAPEKGLEWVA	YISSGSSNIYYADTVKG	RFTISRDNPKNTLFLQMTSLRSEDTAMYYCAR	GYYGNYDAMDY	WGQGTSVTVSS	159
SC16.61	EVLLQRSGPDLVKPGASVTIPCKASGYTFT	DYNMD	WVKQSHGKSLEWIG	NINTYNGGTIYNQKFKG	KATLTVDKPSSTAYMELRSLTSEDTAVYYCAR	RLRYGGHYFDY	WGQGTALTVSS	163
SC16.62	EVMLVESGGDLVKPGGSLKLSCAASGFTFS	SYAMS	WVRQTPEKRLEWVA	YISGGGDHIYYPDSVRG	RFTISRDNAKDTLYLQMSSLRSEDTALYDCAR	VRDWYFDV	WGAGTTVTVSS	167
SC16.63	QVQLQQSGTELLRPGASVKISCKATGYTFS	SYWME	WVKQRPGHGLEWIG	EILPGSGTTQYNEKFKG	KATFTADTSSNTAYMHLSSLTSEDSAVYYCAR	GTNSL	WGQGTLVTVSA	171
SC16.65	QVTLKESGPGILQPSQTLSLTCSFSGFSLS	TSGMGVG	WIRQPSGKGLEWLA	LIWWDDVKRYNPALKS	RLTISKDASSSQVFLKIASVDTADTATYYCAR	IASYDYDVVYAMDY	WGQGTSVSVSS	175
SC16.67	EVQLVETGGGLVQPKGSLKLSCAVSAFTFT	TYAMN	WVRQAPGKGLEWVA	RIRNKSNNYATYYADSVKD	RFTISRDDSQSMLYLQMNNLKIEDTAMYYCVF	YYDYVY	WGQGTLVTVSA	179

FIG. 3B cont.

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Heavy Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.68	QVQLQQPGAELVKPGASVKMSCKASGYTFT	NYNMH	WVKQTPGQGLEWIG	AIFPGNGGTSYNQKFKG	KATLTADKSSSTAYMQLTSLTSGDSAVYYCAR	WGYGSGLYAMDY	WGQGTSVTVSS	183
SC16.72	EVQLQQSGPELVKPGASVKMSCKASGYTFT	SYVMH	WVKQKPGQGLEWIG	YINPYNDGTKYNEKFKG	KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR	LRSRAMDY	WGQGTSVTVSS	187
SC16.73	QVQLQQSGAELMKPGASVKISCKANGYTFS	SYWIE	WLRQRPGHGLEWIG	EILPGSDNSNYNEKFKG	KATFTADTSSNTAYMQLSSLTSEESAVYYCTR	GLRRDGSYYYVMEH	WGQGTSVTVSS	191
SC16.78	EVKLVESGGGLVKPGGSLKLSCAASGFTFG	RYVMS	WVRQTPEKKLEWVA	SITSGGTTYYPDSVKG	RFTISRDNARNILYLQMSSLRSEDTAMYYCAR	VYYHYDDIFAY	WGQGTLVTVSA	195
SC16.79	EVQLQQSGPELVKPGASVKISCKTSGYTFT	EYTMH	WVKQSHGKSLEWIG	GINPNNGGTSYNQKFKG	KATLTVDKSSSTAYMELRSLTSEDSAVYYCAR	GPAWFAY	WGQGTLVTVSA	199
SC16.80	EVQLQQSGPELVKPGGSKKISCKASGYSFT	GYSMN	WVKQSHGKNLEWIG	LINPYSGGTIYNQKFKG	KATLTVDKSSSTAYMELLSLTSEDSAVYYCAR	RSDYPLVY	WGQGTLVTVSA	203
SC16.81	QVQLKESGPVLVAPSQSLSITCTVSGFSLT	SYGVH	WVRQPPGKGLEWLG	VIWAGGSTNYNSALMS	RLSISKDNSKSQVFLKMNSLQTDDTAMYYCAK	QGNFYAMDY	WGQGTSVTVSS	207
SC16.84	EVQLQQSGPELVKPGASMKISCKASGYSFT	GYTMN	WVKQSHGKNLEWIG	LINPYNGGTTYNQKFKG	KATLTVDKSSSTAYMELLSLTSEDSAVYYCAL	GYYGNYRRYFDV	WGAGTTVTVSS	211
SC16.88	QVQLQQSGAELARPGASVKLSCKASGYTCT	SYWMQ	WVKQRPGQGLEWIG	AIYPGDGDTRYTQKFKG	KATLTADKSSSTAYMQLSSLASEDSAVYYCAR	GRRTEAWFAY	WGQGTLVTVSA	215
SC16.101	QVTLKESGPGILQPSQTLSLTCSFSGFSLS	TSGMGVG	WIRQPSGKGLEWLA	HIWWDDVKRYNPALKS	RLTISKDASSSQVFLKIASVDTAETATYYCAH	ILDRAYYFDY	WGQGTTLTVTS	219
SC16.103	QVTLKESGPGILKPSQTLSLTCSFSGFSLS	TSGMGIG	WIRQPSGKGLEWLA	HIWWDDDKYYNPSLKS	QLTISKDSSRNQVFLKITSVDTADTATYYCAR	RGTAYYFDY	WGQGTTLTVSS	223
SC16.104	QVQLKESGPDLVQPSQTLSLTCTVSGFSLT	FYGVH	WVRQPPGKGLEWVG	TMGWDDKKYYNSALKS	RLSISRDTSKNQVFLKLSSLQTEDTAMYYCTR	GGTGFDY	WGQGTTLTVSS	227
SC16.105	QVQLQQPGAELVKPGASVKLSCKASGYTFT	SYWMH	WVKQRPGQGLEWIG	VINPSNGRTNYNEKFKS	KATLTVDKSSSTAYMQLSSLTSEDSAVYYCAR	RRELGTLYAMDY	WGQGTSVTVSS	231
SC16.106	QVQLKQSGPGLVAPSQSLFITCTVSGFSLT	SYEIN	WVRQPPGKGLEWLG	VIWTGGSTNYNSALIS	RLSISKDNSKSLVFLKMNSLQTDDTAIYYCVR	GVYAMDY	WGQGTSVTVSS	235
SC16.107	EVQLQQSGPELVKPGASVKMSCKASGYTFT	NYVMH	WVKQKPGQGLEWIG	YINPYNDGTKYNEKFKG	KATLTSDKSSTTAYMALSSLTSEDSAVYYCAV	AYYSNWGFAY	WGQGTLVTVSA	239
SC16.108	QVQLEESGAELARPGASVKLSCKASGYSYW	MQ	WIKQRPGQGLEWIG	AIYPGNGDTRYTQKFKG	KATLTADKSSSTAYMQLSSLASEDSAVYYCAR	SPAYYRYGEGYFDY	WGQGTTLTVSS	243
SC16.109	QIQLVQSGPELKKPGETVKISCKASGYTFT	NYGMN	WVKQAPGKGLKWMG	WINTYTGEPAYADDFKG	RFAFSLETSASAAYLQINNLKNEDTATFFCAN	MRPTRGFAY	WGQGTLGTVSA	247
SC16.110	EVQLQQSGPGLVRTGASVKISCKASGYSFT	GYYMH	WVKQSHGKSLEWIG	YISCYNGATTYNQNFKG	KATFIVDTSSSTAYMQFNSLTSEDSAVYYCAR	SDGGHAMDY	WGQGTSVTVSS	251
SC16.111	EVQLQQSGPELEKPGASVKISCKASGYSFT	GYNMN	WVKQSNGKSLEWIG	NIDPYYGGSSYKQKFEG	KATLTVDKSSSTAYMQLKSLTSEDSAVYYCAR	GGSNFFDY	WGQGTTLTVSS	255

FIG. 3B cont.

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Heavy Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.113	DVKLVESGGGLVKPGGSLKLSCAASGFTFS	SYTMS	WVRQTPEKRLEWVA	TISSGGSYPYYPDSVKG	RFTISRDNAKNTLYLQMSSLKSEDTAMYYCTR	DVYDGYSY	WGQGTTLTVSS	259
SC16.114	EVQLQQSGAELVKPGASVKLSCTASGFNIK	DTYIH	WVKQRPEQGLEWIG	RIDPANGNTKYDPKFQG	KATITPDTSSNTAYLQLSSLTSEDTAVYYCAR	SWRNYGSSFWYFDV	WGAGTTVTVSS	263
SC16.115	DVKLVESGGGLVKPGGSLKLSCAASGFTFS	SYTMS	WVRQTPEKRLEWVA	TISSGGSYPYYPDSVKG	RFTISRDNAKNTLYLQMSSLKSEDTAMYYCTR	DVYDGYSY	WGQGTTLTVSS	267
SC16.116	QVQLKQSGPGRVQPSQSLSITCTVSGFSLT	SNGVH	WVRQSPGKGLEWLG	VLWSGGSTDYNAAFIS	RLSISKDNYKSQVFFKMNSLQANDTAIYYCAR	NNNRYGAMDY	WGQGTSVTVSS	271
SC16.117	QVQLKESGPGLVAPSQSLSITCTVSGFSLT	NYGVH	WVRQPPGKGLEWLG	VIWAGGITNYNSALMS	RLSISEDNSKSQVFLKMNSLQTDDTAMYYCAR	NLGPYAMDY	WGQGTSVTVSS	275
SC16.118	EVQLQQSGPDLVKPGASVKISCKASGYSFT	GYYMH	WVKQSHGKSLEWIG	RVNPNNGGTSYNQKFKG	KAILTADKSSSTAYMELRSLTSEDSAVYYCAR	GSYDYAEG	WGQGTLVTVSA	279
SC16.120	EIQLQQSGPELVKPGASVKVSCKASGYAFT	SYNMY	WVMQSHGKSLEWIG	YVDPYNGGTSYNQKFKG	KATLTVDKSSSTAYMHLNSLTSEDSAVYYCAR	ENYRYFDY	WGQGTTLTVSS	283
SC16.121	EVQLVESGGGLVQPKGSLKLSCAASGFTFN	TYAMN	WVRQAPGKGLEWVA	RIRIKSNNYATYYADSVKD	RFTISRDDSQNMLYLQMNNLKTEDTAVYYCVR	QGYSYDWGPWFAY	WGQGTLVTVSA	287
SC16.122	EVQLVESGGGLVKPGGSLKLSCAASGFTFS	DYYMF	WVRQTPEKRLEWVA	TISDGGSYTYFPDSVKG	RFTISRDNAQNNLYLQMSSLKSEDTAMYYCAR	AGTLYAMDY	WGQGTSVTVSS	291
SC16.123	QVALKESGPGILQPSQTLSLTCSFSGFSLS	TSGMGVG	WIRQPSGKGLEWLA	HIWWDDVKRYNPALKS	RLTISKDTSSSQVFLKIASVDTADTATYYCAR	MEDYGSSSYFDF	WGHGTTLTVSS	295
SC16.124	EVQLQQSGPELVKPGASVKMSCKASGYTFT	SYVMH	WVKQKPGQGLEWIG	YINPYNDGTKYNEKFKG	KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR	GALYYGNYLGYFDV	WGAGTTVTVSS	299
SC16.125	DVQLQESGPDLVKPSQSLSLTCTVTGYSIT	SGYSWH	WIRQFPGNKLEWMG	YIHYSGSTNYNPSLKS	RISITRDTSKNQFFLQFKSVTTEDSATYYCAL	EGNYDGFAY	WGQGTLVTVS**S**	303
SC16.126	QVQMKESGPGLVAPSQSLSITCTVSGSSLT	NYGVH	WVRQPPGKGLEWLG	VIWAGGSTNYNSALMS	RLSISKDNSKSQVFLKMNSLQTDDTAMYYCAR	DWEGWFAY	WGQGTLVTVSA	307
SC16.129	QVQLKESGPGLVAPSQSLSITCTVSGFSLT	DYGVS	WIRQPPGKGLEWLG	VIWGGGSTYYNSALKS	RLSISKDNSKSQVFLELNSLQTDDTAIYYCAK	HYGHYAAY	WGQGTLVTVSA	311
SC16.130	EVQLQQSGPELVKPGASVKMSCKASGYTFT	SYVMH	WVKQKPGQGLEWIG	YINPYNDGTEYNEKFKG	KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR	GVYDGYSYFDY	WGQGTTLTVSS	315
SC16.131	QVQLKESGPGLVAPSQSLSITCTVSGFSLT	NYGVH	WVRQPPGKGLEWLG	VIWAGGITNYNSALMS	RLSISEDNSKSQVFLKMNSLQTDDTAMYYCAR	NLGPYAMDY	WGQGTSVTVSS	319
SC16.132	QVQLKESGPGLVAPSQSLSITCTVSGFSLT	DYGVS	WIRQPPGKGLEWLG	VVWGGGSTYYNSALKS	RLSITKDNSKSQVFLKMNSLQTDDTAMYYCAK	QRGQYGAY	WGQGTLVTVSA	323
SC16.133	QVQLKESGPGLVAPSQSLSITCTVSGFSLT	NYAVH	WVRQSPGKGLEWLG	VIWSDGSTDYNAAFIS	RLSISKDNSKSQVFFKMNSLQADDTAMYYCAR	KKGGWFPWFAY	WGQGTLVTVSA	327
SC16.134	EVQLQQSGPDLVKPGASVKISCKASGYSFT	GYYMH	WVKQSHGKRLEWIG	RVNPNNGGTNYNQKFKG	KAILTVDKSSSTAYMELRSLTSEDSAVYYCAR	GSYDNAEG	WGQGTLVTVSA	331
SC16.135	QVQLQQSGAELVRPGTSVKVSCKASGYAFT	NYLIE	WVKQRPGQGLEWIG	VINPGSGGTNSNEKFKA	KATLTADKSSSTAYMQLSSLTSADSAVYFCAR	SDYDYAFYAMDY	WGQGTSVTVSS	335
SC16.136	EVQLQQSGPELVKPGASVKMSCKASGYTFT	SYVMH	WVKQKPGQGLEWIG	YINPYNDGTKYNEKFKG	KATLTSDKSSSTAYMELSSLTSEDSAVYYCAR	DRSGYEDYYGMDY	WGQGTSVTVSS	339

FIG. 3B cont.

Amino Acid Sequences of Exemplary Murine anti-DLL3 Antibody Heavy Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
SC16.137	EVQLVESGGDLVKPGGSLKLSCAASGFTFS	SYGMS	WVRQTPDKRLEWVA	TISSGGSYTYYPDSVKG	RFTISRDNAKNTLYLQMSSLKSEDTAMYYCAR	RRADAMDY	WGQGTSVTVSS	343
SC16.138	QVQLKESGPGLVAPSQSLSITCTVSGFSLT	DYGVS	WIRQPPGKGLEWLG	VVWGGGSTYYNSALKS	RLSISKDNSKSQVFLKMNSLQTDDTAMYYCAK	QRGQYGAY	WGQGTLVTVSA	347
SC16.139	EVQLQQSGPELVKPGASVKMSCKASGYTFT	NYVMH	WVKQKPGQGLEWIG	YINPYNDGTKYNEKFKG	KATLTSDKSSTTAYMALSSLTSEDSAVYYCAV	AYYSNWGFAY	WGQGTLVTVSA	351
SC16.140	QVQLQQSGPELVRPGASVKMSCKASGYTFT	SYWMH	WVKQRPGQGLEWIG	MIDPSNSETRLNQKFKD	KATLNVDKSSNTAYMQLSSLTSEDSAVYYCAV	MDYYFDY	WGQGTTLTVSS	355
SC16.141	QVQLKQSGPGLVAPSQSLFITCTVSGFSLT	SYEIN	WVRQPPGKGLEWLG	VIWTGGSTNYNSALIS	RLSISKDNSKSLVFLKMNSLQTDDTAIYYCVR	GVYAMDY	WGQGTSVTVSS	359
SC16.142	EVQLQQSGPELVKPGASVKISCKASGYTFT	DYNMH	WVKQSHGKSLEWIG	FFYPYNGNTVYSQKFKS	KATLTVDNSSSTAYMELRSLTSEDSAVYYCAR	LNWEGY	WGQGTTL<u>TVSS</u>	363
SC16.143	QVQLQQSGPELVKPGASVRISCKASGYTFT	SYYIH	WVKQRPGQGLEWIG	WIYPGNGNTKYNEKFKG	KATLTADKSSSTAYMQISSLTSEDSAVYFCAR	ERWLLLWFAY	WGQGTLVTVSA	367
SC16.144	QIQLVQSGPELKKPGETVKISCKASGYTFT	NYGMN	WVKQAPGKGLKWVG	WINTYTGEPTYADDFKG	RFAFSLETSASTAYLQIDNLKNEDTATYFCAR	VGDYVGFDY	WGQGTTLTVSS	371
SC16.147	QIQLVQSGPELTKPGETVKISCKASGYTFT	DYSLH	WVKQALGKGLKWMG	WINTETGEPAYADDFKG	RFAFSLETSASTAYLQINDLKNEDTTTYFCGI	YDGYAMDY	WGQGTSVTVSS	375
SC16.148	QIQLVQSGPELKKPGETVKISCKASGYTLT	NYGMN	WVKQAPGKGLKWMG	WINTYTGEPTYADDFKG	RFAFSLETSARIVYLQINNLKNEDTATYFCAK	YEAHEGFVY	WGQGTLVTVSA	379
SC16.149	QVQLKESGPGLVAPSQSLSITCAVSGFSLT	SFGVH	WVRQPPGKGLEWLG	VIWAGGSTNYYSALMS	RLSISIDNSKSQVFLKMNSLQTDDTAMYYCAR	DWEGWFAY	WGQGTLVTVSA	383
SC16.150	EIQLQQSGPELVKPGASVKVSCKASGYAFT	SYNMY	WVSQSHGKSLEWIG	YIDPYNGGTSYNQKFRG	KATLTVDKSSSTAYMHLNSLTSEDSAVYYCAR	ENYRYFDF	WGQGTTLTVSS	387

FIG. 3B cont.

Amino Acid Sequences of Exemplary Humanized anti-DLL3 Antibody Heavy Chain Variable Regions

mAb	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4	SEQ ID NO.
hSC16.13	QITLKESGPTLVKPTQTLTLTCTFSGFSLS	TSGMGVG	WIRQPPGKALEWLA	HIWWDDVKRYSPSLKS	RLTITKDTSKNQVVLTMTNMDPVDTATYYCAR	IVSFDNDVVSAMDY	WGQGTLVTVSS	391
hSC16.15	QVQLVQSGAEVKKPGASVKVSCKASGYTFT	RYWIH	WIRQAPGQGLEWMG	YINPTTVYTEFNQNFKD	RVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR	GGSNFFDY	WGQGTTVTVSS	395
hSC16.25	QITLKESGPTLVKPTQTLTLTCTFSGFSLS	TSGMGVG	WIRQPPGKALEWLT	DIWWDDNKYYNPSLKS	RLTITKDTSKNQVVLTMTNMDPVDTATYYCAR	RVNYYYDPYYAMDY	WGQGTLVTVSS	399
hSC16.34	QVQLVQSGAEVKKPGASVKVSCKASGYTFT	NYGMN	WVRQAPGQRLEWMG	WINTYTGDPTYADDFKG	RVTITRDTSASTAYMELSSLRSEDTAVYYCAR	IGGNSPSDY	WGQGTTVTVSS	403
hSC16.56	QVQLVQSGAEVKKPGASVKVSCKASGYTFT	NYGMN	WVRQAPGQGLEWMG	WINTYTGEPTYADDFKG	RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR	IGDSSPSDY	WGQGTLVTVSS	407

FIG. 3B cont.



Domain-level Mapping Summary of Selected DLL3 Antibodies
16.1, 16.5(C), 16.15(G), 16.18(A), 16.19, 16.23(A), 16.25(C), 16.34(D), 16.41, 16.42(A), 16.51, 16.56(D), 16.109, 16.111(D), 16.140, 16.144(G), 16.148(D)
16.46, 16.61, 16.132(H)
16.3(B), 16.10, 16.13(B), 16.16, 16.30(B), 16.32, 16.35, 16.40, 16.47(A), 16.52, 16.65(B), 16.68, 16.81, 16.101(I), 16.120(A), 16.123(H), 16.150(H)
16.62, 16.67, 16.55, 16.79, 16.84, 16.122, 16.148
16.4(F), 16.11, 16.26(B), 16.27, 16.44, 16.125, 16.126, 16.130(A), 16.136, 16.147(A/H), 16.149(A/H)
16.8(A), 16.14, 16.20(A), 16.21, 16.45(A) , 16.135
16.39(I), 16.118, 16.134, 16.141(H)
DSL 176-215
EGF 1 216-249
EGF 2 274-310
EGF 3 312-351
EGF 4 353-389
EGF 5 391-427
EGF 6 429-465

FIG. 4

Biochemical Characteristics of Selected DLL3 Modulators

Clone	Bin	Domain	Affinity (nM)	Cyno XR	Mouse & Rat XR
SC16.4	F	EGF4	0.5[F]	N.D.	Yes
SC16.8	A	EGF5	0.5[F]	N.D.	Yes
SC16.10	E	EGF2	4.0[F]	N.D.	No
SC16.13	B	EGF2	2.0[B]	No[Y]	No
SC16.15	G	N-terminal	0.5[B]	Yes[B]	Yes
SC16.25	C	N-terminal	0.2[B]	Yes[B]	No
SC16.34	D	DSL	0.2[B]	Yes[B]	Yes
SC16.39	I	EGF6	1.0[F]	N.D.	Yes
SC16.46	A	EGF1	0.5[F]	No[Y]	Yes
SC16.51	H	N-terminal	2.0[F]	Yes[B]	Yes
SC16.56	D	DSL	1.0[B]	Yes[B]	Yes
SC16.65	B	EGF2	0.9[B]	No[B]	No
SC16.67	D	EGF3	0.5[F]	Yes[Y]	No

[B] Biacore; [F] ForteBio; [Y] Yeast Display

FIG. 5

Exemplary Antibody Drug Conjugates

ADC #		ADC #		ADC #	
1	SC16.3-DL1	32	SC16.55-DL1	63	SC16.116-DL1
2	SC16.4-DL1	33	SC16.56-DL1	64	SC16.117-DL1
3	SC16.5-DL1	34	SC16.57-DL1	65	SC16.118-DL1
4	SC16.7-DL1	35	SC16.58-DL1	66	SC16.120-DL1
5	SC16.8-DL1	36	SC16.61-DL1	67	SC16.121-DL1
6	SC16.10-DL1	37	SC16.62-DL1	68	SC16.122-DL1
7	SC16.11-DL1	38	SC16.63-DL1	69	SC16.123-DL1
8	SC16.13-DL1	39	SC16.65-DL1	70	SC16.124-DL1
9	SC16.15-DL1	40	SC16.67-DL1	71	SC16.125-DL1
10	SC16.18-DL1	41	SC16.68-DL1	72	SC16.126-DL1
11	SC16.19-DL1	42	SC16.72-DL1	73	SC16.129-DL1
12	SC16.20-DL1	43	SC16.73-DL1	74	SC16.130-DL1
13	SC16.21-DL1	44	SC16.78-DL1	75	SC16.131-DL1
14	SC16.22-DL1	45	SC16.79-DL1	76	SC16.132-DL1
15	SC16.23-DL1	46	SC16.80-DL1	77	SC16.133-DL1
16	SC16.25-DL1	47	SC16.81-DL1	78	SC16.134-DL1
17	SC16.26-DL1	48	SC16.84-DL1	79	SC16.135-DL1
18	SC16.29-DL1	49	SC16.88-DL1	80	SC16.136-DL1
19	SC16.30-DL1	50	SC16.101-DL1	81	SC16.137-DL1
20	SC16.31-DL1	51	SC16.103-DL1	82	SC16.138-DL1
21	SC16.34-DL1	52	SC16.104-DL1	83	SC16.139-DL1
22	SC16.35-DL1	53	SC16.105-DL1	84	SC16.140-DL1
23	SC16.36-DL1	54	SC16.106-DL1	85	SC16.141-DL1
24	SC16.38-DL1	55	SC16.107-DL1	86	SC16.142-DL1
25	SC16.41-DL1	56	SC16.108-DL1	87	SC16.143-DL1
26	SC16.42-DL1	57	SC16.109-DL1	88	SC16.144-DL1
27	SC16.45-DL1	58	SC16.110-DL1	89	SC16.147-DL1
28	SC16.47-DL1	59	SC16.111-DL1	90	SC16.148-DL1
29	SC16.49-DL1	60	SC16.113-DL1	91	SC16.149-DL1
30	SC16.50-DL1	61	SC16.114-DL1	92	SC16.150-DL1
31	SC16.52-DL1	62	SC16.115-DL1		

FIG. 6

Exemplary Antibody Drug Conjugates

ADC #		ADC #		ADC #	
93	SC16.3-DL2	124	SC16.55-DL2	155	SC16.116-DL2
94	SC16.4-DL2	125	SC16.56-DL2	156	SC16.117-DL2
95	SC16.5-DL2	126	SC16.57-DL2	157	SC16.118-DL2
96	SC16.7-DL2	127	SC16.58-DL2	158	SC16.120-DL2
97	SC16.8-DL2	128	SC16.61-DL2	159	SC16.121-DL2
98	SC16.10-DL2	129	SC16.62-DL2	160	SC16.122-DL2
99	SC16.11-DL2	130	SC16.63-DL2	161	SC16.123-DL2
100	SC16.13-DL2	131	SC16.65-DL2	162	SC16.124-DL2
101	SC16.15-DL2	132	SC16.67-DL2	163	SC16.125-DL2
102	SC16.18-DL2	133	SC16.68-DL2	164	SC16.126-DL2
103	SC16.19-DL2	134	SC16.72-DL2	165	SC16.129-DL2
104	SC16.20-DL2	135	SC16.73-DL2	166	SC16.130-DL2
105	SC16.21-DL2	136	SC16.78-DL2	167	SC16.131-DL2
106	SC16.22-DL2	137	SC16.79-DL2	168	SC16.132-DL2
107	SC16.23-DL2	138	SC16.80-DL2	169	SC16.133-DL2
108	SC16.25-DL2	139	SC16.81-DL2	170	SC16.134-DL2
109	SC16.26-DL2	140	SC16.84-DL2	171	SC16.135-DL2
110	SC16.29-DL2	141	SC16.88-DL2	172	SC16.136-DL2
111	SC16.30-DL2	142	SC16.101-DL2	173	SC16.137-DL2
112	SC16.31-DL2	143	SC16.103-DL2	174	SC16.138-DL2
113	SC16.34-DL2	144	SC16.104-DL2	175	SC16.139-DL2
114	SC16.35-DL2	145	SC16.105-DL2	176	SC16.140-DL2
115	SC16.36-DL2	146	SC16.106-DL2	177	SC16.141-DL2
116	SC16.38-DL2	147	SC16.107-DL2	178	SC16.142-DL2
117	SC16.41-DL2	148	SC16.108-DL2	179	SC16.143-DL2
118	SC16.42-DL2	149	SC16.109-DL2	180	SC16.144-DL2
119	SC16.45-DL2	150	SC16.110-DL2	181	SC16.147-DL2
120	SC16.47-DL2	151	SC16.111-DL2	182	SC16.148-DL2
121	SC16.49-DL2	152	SC16.113-DL2	183	SC16.149-DL2
122	SC16.50-DL2	153	SC16.114-DL2	184	SC16.150-DL2
123	SC16.52-DL2	154	SC16.115-DL2		

FIG. 6 cont.

Exemplary Antibody Drug Conjugates

ADC #		ADC #		ADC #	
185	SC16.3-DL3	216	SC16.55-DL3	247	SC16.116-DL3
186	SC16.4-DL3	217	SC16.56-DL3	248	SC16.117-DL3
187	SC16.5-DL3	218	SC16.57-DL3	249	SC16.118-DL3
188	SC16.7-DL3	219	SC16.58-DL3	250	SC16.120-DL3
189	SC16.8-DL3	220	SC16.61-DL3	251	SC16.121-DL3
190	SC16.10-DL3	221	SC16.62-DL3	252	SC16.122-DL3
191	SC16.11-DL3	222	SC16.63-DL3	253	SC16.123-DL3
192	SC16.13-DL3	223	SC16.65-DL3	254	SC16.124-DL3
193	SC16.15-DL3	224	SC16.67-DL3	255	SC16.125-DL3
194	SC16.18-DL3	225	SC16.68-DL3	256	SC16.126-DL3
195	SC16.19-DL3	226	SC16.72-DL3	257	SC16.129-DL3
196	SC16.20-DL3	227	SC16.73-DL3	258	SC16.130-DL3
197	SC16.21-DL3	228	SC16.78-DL3	259	SC16.131-DL3
198	SC16.22-DL3	229	SC16.79-DL3	260	SC16.132-DL3
199	SC16.23-DL3	230	SC16.80-DL3	261	SC16.133-DL3
200	SC16.25-DL3	231	SC16.81-DL3	262	SC16.134-DL3
201	SC16.26-DL3	232	SC16.84-DL3	263	SC16.135-DL3
202	SC16.29-DL3	233	SC16.88-DL3	264	SC16.136-DL3
203	SC16.30-DL3	234	SC16.101-DL3	265	SC16.137-DL3
204	SC16.31-DL3	235	SC16.103-DL3	266	SC16.138-DL3
205	SC16.34-DL3	236	SC16.104-DL3	267	SC16.139-DL3
206	SC16.35-DL3	237	SC16.105-DL3	268	SC16.140-DL3
207	SC16.36-DL3	238	SC16.106-DL3	269	SC16.141-DL3
208	SC16.38-DL3	239	SC16.107-DL3	270	SC16.142-DL3
209	SC16.41-DL3	240	SC16.108-DL3	271	SC16.143-DL3
210	SC16.42-DL3	241	SC16.109-DL3	272	SC16.144-DL3
211	SC16.45-DL3	242	SC16.110-DL3	273	SC16.147-DL3
212	SC16.47-DL3	243	SC16.111-DL3	274	SC16.148-DL3
213	SC16.49-DL3	244	SC16.113-DL3	275	SC16.149-DL3
214	SC16.50-DL3	245	SC16.114-DL3	276	SC16.150-DL3
215	SC16.52-DL3	246	SC16.115-DL3		

FIG. 6 cont.

Exemplary Antibody Drug Conjugates

ADC #		ADC #		ADC #	
277	SC16.3-DL4	308	SC16.55-DL4	339	SC16.116-DL4
278	SC16.4-DL4	309	SC16.56-DL4	340	SC16.117-DL4
279	SC16.5-DL4	310	SC16.57-DL4	341	SC16.118-DL4
280	SC16.7-DL4	311	SC16.58-DL4	342	SC16.120-DL4
281	SC16.8-DL4	312	SC16.61-DL4	343	SC16.121-DL4
282	SC16.10-DL4	313	SC16.62-DL4	344	SC16.122-DL4
283	SC16.11-DL4	314	SC16.63-DL4	345	SC16.123-DL4
284	SC16.13-DL4	315	SC16.65-DL4	346	SC16.124-DL4
285	SC16.15-DL4	316	SC16.67-DL4	347	SC16.125-DL4
286	SC16.18-DL4	317	SC16.68-DL4	348	SC16.126-DL4
287	SC16.19-DL4	318	SC16.72-DL4	349	SC16.129-DL4
288	SC16.20-DL4	319	SC16.73-DL4	350	SC16.130-DL4
289	SC16.21-DL4	320	SC16.78-DL4	351	SC16.131-DL4
290	SC16.22-DL4	321	SC16.79-DL4	352	SC16.132-DL4
291	SC16.23-DL4	322	SC16.80-DL4	353	SC16.133-DL4
292	SC16.25-DL4	323	SC16.81-DL4	354	SC16.134-DL4
293	SC16.26-DL4	324	SC16.84-DL4	355	SC16.135-DL4
294	SC16.29-DL4	325	SC16.88-DL4	356	SC16.136-DL4
295	SC16.30-DL4	326	SC16.101-DL4	357	SC16.137-DL4
296	SC16.31-DL4	327	SC16.103-DL4	358	SC16.138-DL4
297	SC16.34-DL4	328	SC16.104-DL4	359	SC16.139-DL4
298	SC16.35-DL4	329	SC16.105-DL4	360	SC16.140-DL4
299	SC16.36-DL4	330	SC16.106-DL4	361	SC16.141-DL4
300	SC16.38-DL4	331	SC16.107-DL4	362	SC16.142-DL4
301	SC16.41-DL4	332	SC16.108-DL4	363	SC16.143-DL4
302	SC16.42-DL4	333	SC16.109-DL4	364	SC16.144-DL4
303	SC16.45-DL4	334	SC16.110-DL4	365	SC16.147-DL4
304	SC16.47-DL4	335	SC16.111-DL4	366	SC16.148-DL4
305	SC16.49-DL4	336	SC16.113-DL4	367	SC16.149-DL4
306	SC16.50-DL4	337	SC16.114-DL4	368	SC16.150-DL4
307	SC16.52-DL4	338	SC16.115-DL4		

FIG. 6 cont.

Exemplary Antibody Drug Conjugates

ADC #		ADC #		ADC #	
369	SC16.3-DL5	400	SC16.55-DL5	431	SC16.116-DL5
370	SC16.4-DL5	401	SC16.56-DL5	432	SC16.117-DL5
371	SC16.5-DL5	402	SC16.57-DL5	433	SC16.118-DL5
372	SC16.7-DL5	403	SC16.58-DL5	434	SC16.120-DL5
373	SC16.8-DL5	404	SC16.61-DL5	435	SC16.121-DL5
374	SC16.10-DL5	405	SC16.62-DL5	436	SC16.122-DL5
375	SC16.11-DL5	406	SC16.63-DL5	437	SC16.123-DL5
376	SC16.13-DL5	407	SC16.65-DL5	438	SC16.124-DL5
377	SC16.15-DL5	408	SC16.67-DL5	439	SC16.125-DL5
378	SC16.18-DL5	409	SC16.68-DL5	440	SC16.126-DL5
379	SC16.19-DL5	410	SC16.72-DL5	441	SC16.129-DL5
380	SC16.20-DL5	411	SC16.73-DL5	442	SC16.130-DL5
381	SC16.21-DL5	412	SC16.78-DL5	443	SC16.131-DL5
382	SC16.22-DL5	413	SC16.79-DL5	444	SC16.132-DL5
383	SC16.23-DL5	414	SC16.80-DL5	445	SC16.133-DL5
384	SC16.25-DL5	415	SC16.81-DL5	446	SC16.134-DL5
385	SC16.26-DL5	416	SC16.84-DL5	447	SC16.135-DL5
386	SC16.29-DL5	417	SC16.88-DL5	448	SC16.136-DL5
387	SC16.30-DL5	418	SC16.101-DL5	449	SC16.137-DL5
388	SC16.31-DL5	419	SC16.103-DL5	450	SC16.138-DL5
389	SC16.34-DL5	420	SC16.104-DL5	451	SC16.139-DL5
390	SC16.35-DL5	421	SC16.105-DL5	452	SC16.140-DL5
391	SC16.36-DL5	422	SC16.106-DL5	453	SC16.141-DL5
392	SC16.38-DL5	423	SC16.107-DL5	454	SC16.142-DL5
393	SC16.41-DL5	424	SC16.108-DL5	455	SC16.143-DL5
394	SC16.42-DL5	425	SC16.109-DL5	456	SC16.144-DL5
395	SC16.45-DL5	426	SC16.110-DL5	457	SC16.147-DL5
396	SC16.47-DL5	427	SC16.111-DL5	458	SC16.148-DL5
397	SC16.49-DL5	428	SC16.113-DL5	459	SC16.149-DL5
398	SC16.50-DL5	429	SC16.114-DL5	460	SC16.150-DL5
399	SC16.52-DL5	430	SC16.115-DL5		

FIG. 6 cont.

Exemplary Humanized Antibody Drug Conjugates

ADC #		ADC #		ADC #		ADC #		ADC #	
461	hSC16.13-DL1	466	hSC16.13-DL2	471	hSC16.13-DL3	476	hSC16.13-DL4	481	hSC16.13-DL5
462	hSC16.15-DL1	467	hSC16.15-DL2	472	hSC16.15-DL3	477	hSC16.15-DL4	482	hSC16.15-DL5
463	hSC16.25-DL1	468	hSC16.25-DL2	473	hSC16.25-DL3	478	hSC16.25-DL4	483	hSC16.25-DL5
464	hSC16.34-DL1	469	hSC16.34-DL2	474	hSC16.34-DL3	479	hSC16.34-DL4	484	hSC16.34-DL5
465	hSC16.56-DL1	470	hSC16.56-DL2	475	hSC16.56-DL3	480	hSC16.56-DL4	485	hSC16.56-DL5

FIG. 6 cont.